H.C. Wainwright

Karyopharm Therapeutics Inc (NASDAQ: KPTI) shares, which suffered a setback in late February following the release of the FDA's briefing document and panel vote on its multiple myeloma treatment candidate Selinexor, were seeing upward momentum on double their average volume Friday. What...

Biogen Inc (NASDAQ: BIIB) announced Monday a deal to buy gene therapy biotech Nightstar Therapeutics PLC (NASDAQ: NITE) for $800 million. The Analysts Baird analyst Brian Skorney maintained a Neutral rating on Biogen with a $348 price target. H.C. Wainwright analyst Andrew Fein reiterated a Buy...

La Jolla Pharmaceutical Company (NASDAQ: LJPC) reported net 2018 sales of $10.1 million for the septic shock treatment Giapreza this week and announced 2019 sales guidance of $24 million to $28 million for the drug.  The guidance represents continued linear growth, despite the company...

NeuroMetrix Inc (NASDAQ: NURO) is a commercial-stage health care technology company with two products on the market: Quell, an OTC wearable device relying on neurostimulation technology for chronic pain relief; and DPNCheck, a point-of-care diabetic peripheral neuropathy test. With $...

Stemline Therapeutics Inc (NASDAQ: STML) has received FDA approved for Elzonris ahead of the Feb. 21 PDUFA date. The approval coming in two months early highlights “the urgent need” in the indication, according to H.C. Wainwright. The Analyst Analyst Raghuram Selvaraju initiated...

Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) has Phase 3 trials ongoing for its lead compound lenabasum in systemic sclerosis and dermatomyositis, and Phase 2 trials for cystic fibrosis and systemic lupus erythematosus. With cannabinoid receptor type 2 being a critical component of...

Insmed Incorporated (NASDAQ: INSM) stock crashed Monday after the U.S. Food & Drug Administration approved the company’s antibiotic Arikayce. In addition to “sell the news” traders moving on following the FDA approval, some sellers are likely concerned about the revelation...

Amarin Corp. (NASDAQ: AMRN) shares surged Monday after the company reported positive cardiovascular trial results for its fish oil capsules.   The Analyst H.C. Wainwright & Co. analyst Andrew S. Fein reiterated a Buy rating on Amarin and raised the price target from $10 to $...

Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) stock plummeted 17.8 percent at Thursday’s open after the company ended a Phase 1 study for ZYN001, a tetrahydrocannabinol patch. While there were no adverse effects, the drug failed to meet the targeted top-line results. Shares regained ground...

Sarepta Therapeutics Inc. (NASDAQ: SRPT) reported some encouraging results from the first three patients treated with the company’s microdystrophin gene therapy program for Duchenne Muscular Dystrophy (DMD), sending the stock soaring higher by 40 percent Tuesday and prompting positive...

Riot Blockchain Inc (NASDAQ: RIOT) quietly filed a 10-Q quarterly financial report on Thursday evening without issuing a press release or holding a conference call for investors. The filing provided some helpful insight into Riot's cryptocurrency mining business, according to H.C. Wainwright....

After a huge year in 2017, the cryptocurrency market has cooled off so far in 2018. One analyst sees the sell-off in Riot Blockchain Inc (NASDAQ: RIOT) as a buying opportunity. The Analyst H.C. Wainwright analyst Kevin Dede initiated coverage of Riot with a Buy rating and $9 price target. The...

Sellas Life Sciences Group Inc (NASDAQ: SLS) popped as much as 189 percent Monday after reporting “clinically meaningful activity” in interim data for its Phase 2b NeuVax trial. H.C. Wainwright liked the stock before it peaked, though, and it considers NeuVax just a footnote in the...

Analysts at H.C. Wainwright initiated coverage Thursday on two pharmaceutical companies developing cancer-related vaccines and treatments. Interpace: Efficient Diagnosis, Expanding Reimbursement Coverage Analyst Raghuram Selvaraju initiated coverage on Interpace Diagnostics Group, Inc. (NASDAQ:...

DURECT Corporation (NASDAQ: DRRX) has had a rough few months since the failure of a Phase 3 trial for its formerly leading drug candidate. Days after reporting top- and bottom-line quarterly beats, the biotech received support in the form of an upgrade from H.C. Wainwright.  The Rating...